Company intelligence / Profile preview

Chongqing iSIA BIO-Technology

Chongqing, Chongqing, Chinaisiabio.com ↗

Ownership: Private
Development stage: Commercial

Overview

Chongqing iSIA BIO-Technology is the first company globally to establish a QDs Immunofluorescence platform for rapid clinical diagnostics. Their products are commercialized and used for detecting a wide range of conditions with improved sensitivity and accuracy compared to conventional immunoassays. The company is recognized as one of the largest innovative IVD enterprises in China

Therapeutic areas: OncologyImmunologyGastroenterologyCardiovascularNephrologyInfectious Diseases
Modalities: Diagnostic reagentDevice
Industry: Protein Biomarker Diagnostics

Beyond the preview

Go deeper on Chongqing iSIA BIO-Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chongqing iSIA BIO-Technology.

Explore the full profile